Efficacy, tolerability, and parent reported outcomes for cefdinir vs. high-dose amoxicillin/clavulanate oral suspension for acute otitis media in young children

Current Medical Research and Opinion

Volumn 22, Issue 9, 2006, Pages 1839-1847

  Block, Stan L ^a   Schmier, Jordana K ^b   Notario, Gerard F ^c   Akinlade, Bolanle K ^c   Busman, Todd A ^c   MacKinnon III, George E ^c,d   Halpern, Michael T ^b   Nilius, Angela M ^c  

^a Kentucky Pediatric Research Institute   (United States)

^b EXPONENT INC   (United States)

^c ABBOTT LABORATORIES   (United States)

^d AMERICAN ASSOCIATION OF COLLEGES OF PHARMACY   (United States)

Author keywords

Acute otitis media; Amoxicillin clavulanate; Cefdinir

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFDINIR;

ACUTE OTITIS MEDIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPER DERMATITIS; DIARRHEA; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MIDDLE EAR; MULTICENTER STUDY; PARENT; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; PRESCHOOL CHILD; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SATISFACTION; SINGLE BLIND PROCEDURE; SUSPENSION; TASTE PREFERENCE; TELEPHONE; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ACUTE DISEASE; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; MALE; OTITIS MEDIA; PARENTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33749030215     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X132406     Document Type: Article

References (31)

1. American Academy of Pediatrics and American Academy of Family Physicians. Subcommittee on Management of Acute Otitis Media. Clinical practice guideline: diagnosis and management of acute otitis media. Pediatrics 2004;113:1451-65
2. Antimicrobial agents and related therapy: principles of appropriate use for upper respiratory tract infections. In: Pickering LK, Baker CJ, McMillan J, et al., editors. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th edn. Elk Grove Village, IL: American Academy of Pediatrics, 2006. pp.531-2
3. Pichichero ME, Casey JR. Acute otitis media: making sense of recent guidelines on antimicrobial treatment. J Fam Pract 2005;54:313-22
4. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Guidance for industry: acute otitis media - developing antimicrobial drugs for treatment, draft guidance. July 1998
5. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance - a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999; 18:1-9
6. Pichichero ME, Reiner SA, Brook I, et al. Controversies in the medical management of persistent and recurrent acute otitis media. Recommendations of a clinical advisory committee. Ann Otol Rhinol Laryngol Suppl 2000;183:1-12
7. Omnicef® Prescribing Information. Abbott Laboratories ©2005. Available from http://www.abbott.com [Last accessed 16 May 2006]
8. Block SL, McCarty JM, Hedrick JA, et al. Comparative safety and efficacy of cefdinir vs amoxicillin/clavulanate for treatment of suppurative acute otitis media in children. Pediatr Infect Dis J 2000;19(Suppl):S159-65
9. Block SL, Busman TA, Paris MM, et al. Comparison of five-day cefdinir treatment with ten-day low dose amoxicillin/clavulanate treatment for acute otitis media. Pediatr Infect Dis J 2004;23:834-8
10. Block SL, Kratzer J, Nemeth MA, et al. Five-day cefdinir course vs. ten-day cefprozil course for treatment of acute otitis media. Pediatr Infect Dis J 2000;19(Suppl):S147-52
11. Block SL, Cifaldi M, Gu Y, et al. A comparison of 5 days of therapy with cefdinir or azithromycin in children with acute otitis media: a multicenter, prospective, single-blind study. Clin Ther 2005;27:786-94
12. Block SL, Hedrick J, Harrison CJ, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004;23:829-33
13. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344:403-9
14. Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 2004;23:824-8
15. Iwai N. Drug compliance of children and infants with oral antibiotics for pediatric use. Acta Paediatr Jpn 1997;39: 132-42
16. Ramgoolam A, Steele R. Formulations of antibiotics for children in primary care: effects on compliance and efficacy. Paediatr Drugs 2002;4:323-33
17. Dagan R, Shvartzman P, Liss Z. Variation in acceptance of common oral antibiotic suspensions. Pediatr Infect Dis J 1994;13:686-90
18. Steele RW, Thomas MP, Begue RE. Compliance issues related to the selection of antibiotic suspensions for children. Pediatr Infect Dis J 2001;20:1-5
19. Block SL. Short-course antimicrobial therapy of streptococcal pharyngitis. Clin Pediatr 2003;42:663-71
20. Powers JL, Gooch WM 3rd, Oddo LP. Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients. Pediatr Infect Dis J 2000;19(Suppl):S174-80
21. Wandstrat TL, Kaplan B. Pharmacoeconomic impact of factors affecting compliance with antibiotic regimens in the treatment of acute otitis media. Pediatr Infect Dis J 1997;16(Suppl):S27-9
22. D'Agostino RB, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Statist Med 2003;22:169-86
23. Brittain E, Lin D. A comparison of intent-to-treat and perprotocol results in antibiotic inferiority studies. Statist Med 2005;24:1-10
24. Augmentin ES-600® Prescribing Information. GlaxoSmithKline ©2005. Available from http://www.gsk.com [Last accessed 16 May 2006]
25. Cifaldi MA, Paris MM, Devcich KJ, et al. Parent-reported outcomes for treatment of acute otitis media with cefdinir or amoxicillin/clavulanate oral suspensions. Paediatr Drugs 2004;6:387-93
26. Schmier JK, Cifaldi MA, Halpern MT. Validation of the otitis parent questionnaire (OPQ). International Society for Quality of Life Research Symposium; Boston, MA. June 27-29, 2004 [abstract 129]
27. Sanchez MM, Chen X. Choosing the analysis population in non-inferiority studies: per-protocol or intent-to-treat. Statist Med 2006;25:1169-81
28. Carlin SA, Marchant CD, Shurin PA, et al. Host factors and early therapeutic response in acute otitis media. J Pediatr 1991;118:178-83
29. Hoberman A, Paradise JL, Burch DJ, et al. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children. Pediatr Infect Dis J 1997;16: 463-70
30. Cohen R, Levy C, Boucherat M, et al. Five vs. ten days of antibiotic therapy for acute otitis media in young children. Pediatric Infect Dis J 2000;19:458-63
31. Leibovitz E, Greenberg D, Piglansky L, et al. Recurrent acute otitis media occurring within one month from completion of antibiotic therapy: relationship to the original pathogen. Pediatr Infect Dis J 2003;22:209-16